论文部分内容阅读
目的探讨CD56在急性髓细胞白血病(AML)患者中的表达及意义。方法采用多色流式细胞术对102例初诊AML的患者进行免疫表型检测,分析CD56在AML患者中的表达及其与其他分化抗原的相关性。结果 102例AML患者中,23例(22.5%)表达CD56。伴有淋系抗原表达的AML(Ly+AML)组CD56表达率高于Ly-AML组(χ2=9.54,P<0.01),Pearson相关性分析显示,CD56的表达与伴淋系抗原的表达呈正相关(r=0.304,P<0.05),而与年龄、性别、CD7、CD34、CD117及人类白细胞抗原DR的表达无明显相关性。CD56+AML组的完全缓解(CR)率低于CD56-AML组(42.1%vs.74.5%)(χ2=6.91,P<0.05)。多因素Logistic回归分析显示,CD56是影响AML患者CR率的独立危险因素(P<0.05)。CD56+AML的无病生存期(DFS)较CD56-AML短(χ2=18.97,P<0.01)。COX回归多因素分析结果提示,CD56是影响AML患者DFS的独立危险因素(P<0.01)。结论 CD56+AML患者CR率明显降低,DFS明显缩短,预后较差。CD56可作为评估AML患者预后的指标。
Objective To investigate the expression and significance of CD56 in patients with acute myeloid leukemia (AML). Methods 102 cases of newly diagnosed AML patients were immunophenotyped by multicolor flow cytometry. The expression of CD56 in AML patients and its relationship with other differentiated antigens were analyzed. Results Of 102 AML patients, 23 (22.5%) expressed CD56. The expression of CD56 in AML (Ly + AML) group with lymphoid antigen expression was higher than that in Ly-AML group (χ2 = 9.54, P <0.01). Pearson correlation analysis showed that CD56 expression was positively correlated with lymphoid antigen (R = 0.304, P <0.05), but not with age, sex, CD7, CD34, CD117 and human leukocyte antigen DR expression. The complete remission (CR) rate of CD56 + AML group was lower than that of CD56-AML group (42.1% vs 74.5%) (χ2 = 6.91, P <0.05). Multivariate Logistic regression analysis showed that CD56 was an independent risk factor for CR rate in AML patients (P <0.05). The disease-free survival (DFS) of CD56 + AML was shorter than that of CD56-AML (χ2 = 18.97, P <0.01). COX regression multivariate analysis suggested that CD56 was an independent risk factor for DFS in AML patients (P <0.01). Conclusion The CR rate of patients with CD56 + AML is significantly lower, DFS is significantly shorter and the prognosis is poor. CD56 can be used as an index to evaluate the prognosis of AML patients.